Short-term treatment with COX-2 inhibitors does not impair fracture healing.
The effects of cyclooxygenase (COX) inhibition on fracture healing are insufficiently documented, and the aim of this study was to evaluate the effects of nonspecific and specific COX-2 inhibition in the early phase of fracture healing. Thirty rats were randomized in three groups. A diaphyseal fracture was performed and stabilized by intramedullary nailing. In group A parecoxib in a dose of 1 mg/kg body weight/day was given prior to surgery and daily for seven days; in group B diclofenac 2 mg/kg body weight/day was given; and in group C the same amount of saline was given. Blood samples were harvested at 7 and 30 days postoperatively and analyzed for active medications. At 30 days the rats were sacrificed, and the fractures were examined for bone mineralization and tested mechanically. The fractures healed by the production of callus. Plasma concentrations at seven days of medication revealed therapeutic levels of parecoxib, valdecoxib, and diclofenac. There were no significant differences in bone mineralization or mechanical characteristics between the three groups at 30 days postfracture. This study indicates that nonspecific or specific COX-2 inhibitors in therapeutic doses during seven days after fracture do not significantly influence bone healing.